Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459,
in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection.
The study is a double blind, randomised trial in which half the subjects will receive OC459
and the other half placebo, before being inoculated with rhinovirus, that would normally
induce a worsening of asthma symptoms i.e. an exacerbation.
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Atopix Therapeutics, Ltd. Medical Research Council